Document is current
Any future updates will be listed below
-
Authors
Ochoa, Dolores
Román, Manuel
Cabaleiro, Teresa
Saiz-Rodríguez, Miriam
Mejía, Gina
Abad-Santos, Francisco http://orcid.org/0000-0002-6519-8885
-
Funding
Funding for this research was provided by:
Fundación Teófilo Hernando
- License Information
-
More Information
Article History
Received: 3 February 2020
Accepted: 16 July 2020
First Online: 25 July 2020
Ethics approval and consent to participate
: The protocols complied with current Spanish legislation on clinical research in humans and were approved by the Research Ethics Committee from Hospital Universitario de La Princesa, duly authorized by the Spanish Drug Agency and under the guidelines of Good Clinical Practice. All participants gave their written informed consent for genotyping and were free to withdraw from the study at any time. The bioequivalence single-dose clinical trials were performed at Hospital Universitario de La Princesa (Madrid, Spain) between 2006 and 2010.
: Not Applicable.
: F.A.S. and D.O. have been consultants or investigators in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Cinfa, FAES, Farmalíder, Ferrer, GlaxoSmithKline, Galenicum, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Silverpharma, Teva and Zambon. The remaining authors declare no competing interests.
